Get the Stockscreener App
3.95
0.77%
0.03
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Altimmune Inc stock is traded at $3.95, with a volume of 1.34M.
It is up +0.77% in the last 24 hours and up +8.52% over the past month.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$3.92
Open:
$3.92
24h Volume:
1.34M
Relative Volume:
0.48
Market Cap:
$348.62M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-2.4085
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
-1.50%
1M Performance:
+8.52%
6M Performance:
-10.43%
1Y Performance:
-37.30%
1-Day Range:
$3.85
$3.98
1-Week Range:
$3.85
$4.1799
52-Week Range:
$2.90
$11.16
Altimmune Inc Stock (ALT) Company Profile
Name
Altimmune Inc
Sector
Industry
Phone
(240) 654-1450
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.95 | 345.97M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.80 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.19 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.04 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
806.95 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.71 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| Feb-28-25 | Initiated | William Blair | Mkt Perform |
| Jan-08-25 | Initiated | Stifel | Buy |
| Nov-12-24 | Initiated | UBS | Buy |
| Apr-29-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-24-24 | Initiated | Goldman | Neutral |
| Mar-22-23 | Downgrade | Goldman | Buy → Neutral |
| Dec-01-22 | Initiated | Goldman | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-02-21 | Initiated | H.C. Wainwright | Buy |
| Feb-11-21 | Initiated | Guggenheim | Buy |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Nov-12-20 | Reiterated | B. Riley Securities | Buy |
| Sep-25-20 | Initiated | B. Riley FBR | Buy |
| Aug-14-20 | Initiated | Evercore ISI | Outperform |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jul-28-20 | Initiated | JMP Securities | Mkt Outperform |
| Feb-24-20 | Resumed | ROTH Capital | Buy |
| Jul-19-19 | Initiated | ROTH Capital | Buy |
| Oct-09-17 | Initiated | Piper Jaffray | Overweight |
View All
Altimmune Inc Stock (ALT) Latest News
Altimmune (NASDAQ:ALT) Receives Buy Rating from HC Wainwright - MarketBeat
ALT Stock: HC Wainwright & Co. Reiterates 'Buy' Rating with $12 - GuruFocus
Altimmune, Inc. (NASDAQ:ALT) Receives Average Rating of “Hold” from Analysts - Defense World
Altimmune, Inc. (NASDAQ:ALT) Receives Average Rating of "Hold" from Analysts - MarketBeat
ALTIMMUNE ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Pleasing Signs As A Number Of Insiders Buy Altimmune Stock - Yahoo Finance
PFG Investments LLC Has $46,000 Stock Position in Altimmune, Inc. $ALT - Defense World
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Altimmune, Inc.(ALT) Shareholders - Sahm
Investors who lost money on Altimmune, Inc. (ALT) should contact Levi & Korsinsky about pending Class ActionALT - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Business Wire
October 6, 2025 Deadline Approaching: Join Class Action Against Altimmune, Inc. (ALT)Contact Levi & Korsinsky - ACCESS Newswire
ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, - GlobeNewswire
Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your RightsALT - PR Newswire
ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - FinancialContent
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
ALT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Altimmune, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025ALT - Newsfile
Join Class Action to Recover Losses from Altimmune, Inc. (ALT)Contact Levi & Korsinsky Before October 6, 2025 - Newsfile
Altimmune Appoints New Chief Medical Officer - TipRanks
ALTIMMUNE CLASS ACTION REMINDER: Bragar Eagel & Squire, - GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming DeadlinesALT - WV News
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - MarketScreener
ALT Deadline: ALT Investors with Losses in Excess of $50K Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit - Morningstar
Shareholders that lost money on Altimmune, Inc.(ALT) Urged - GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - Newsfile
Altimmune, Inc. (NASDAQ: ALT) Deadline Approaching: Berger Montague Advises Investors of Deadline in Securities Fraud Lawsuit - Prime Publishers, Inc.
Securities Lawsuit Alert: Altimmune, Inc. (ALT) InvestorsContact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
Portnoy Law Firm Announces Class Action on Behalf of Altimmune, Inc. Investors - GlobeNewswire
Shareholders SueWallSt in New Class Action Against Altimmune, Inc.Act Now - Nasdaq
Relative strength of Altimmune Inc. in sector analysisPortfolio Risk Summary & Long-Term Safe Investment Plans - newser.com
ALT DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages - GlobeNewswire
Altimmune at Stifel Forum: Strategic Insights on MASH Drug - Investing.com
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - GlobeNewswire
Altimmune, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – ALT - The Globe and Mail
About Us - FinancialContent
Does Altimmune Inc. qualify in momentum factor screeningStop Loss & Accurate Entry/Exit Alerts - newser.com
Altimmune appoints new chief medical officer to lead pemvidutide program By Investing.com - Investing.com Nigeria
The Gross Law Firm Reminds Altimmune Investors of the - GlobeNewswire
Class Action Lawsuit Filed Against Altimmune, Inc. (ALT)Recover LossesContact Levi & Korsinsky Before October 6, 2025 - ACCESS Newswire
ALTIMMUNE (ALT) DEADLINE ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
ALT Investors Have Opportunity to Lead Altimmune, Inc. Securitie - GuruFocus
Using economic indicators to assess Altimmune Inc. potentialPrice Action & Precise Trade Entry Recommendations - newser.com
Altimmune Appoints Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer - citybiz
Can Altimmune Inc. rally from current levels2025 Price Targets & High Return Stock Watch Alerts - newser.com
Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class ActionALT - Eastern Progress
Altimmune appoints new chief medical officer to lead pemvidutide program - Investing.com
Altimmune Inc Stock (ALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Altimmune Inc Stock (ALT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Mar 13 '25 |
Buy |
5.20 |
10,000 |
51,996 |
10,000 |
| Garg Vipin K | President and CEO |
Feb 02 '25 |
Option Exercise |
0.00 |
18,950 |
0 |
363,364 |
| Garg Vipin K | President and CEO |
Feb 01 '25 |
Option Exercise |
0.00 |
16,545 |
0 |
351,645 |
| Garg Vipin K | President and CEO |
Jan 30 '25 |
Option Exercise |
0.00 |
26,775 |
0 |
342,696 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
84,564 |
| Harris Matthew Scott | Chief Medical Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
78,898 |
| Harris Matthew Scott | Chief Medical Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
74,000 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '25 |
Option Exercise |
0.00 |
7,775 |
0 |
75,536 |
| Roberts M Scot | Chief Scientific Officer |
Feb 01 '25 |
Option Exercise |
0.00 |
6,166 |
0 |
69,562 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '25 |
Option Exercise |
0.00 |
9,275 |
0 |
62,921 |
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):